3WHO. Introduction to drug utilization research [EB/OL]. http://www.who.int/medicines/areas/quality_safety/safety_ efficacy/utilization/en/index.html.2003.2009-10. 被引量：1
4Laing R, Waning B, Gray A, et al. 25 years of the WHO essential medicines lists: progress and challenges[J]. Lancet,2003,361(9 370) : 1 723. 被引量：1
6Berndt ER. Pharmaceuticals in U.S. health care determinants of quantity, and price[J]. Journal of Economic Perspectives, 2002,16 (4): 45-66. 被引量：1
7Kremer M. Pharmaceuticals and the developing world[J]. Journal of Economic Perspectives, 2002, 16(4): 67-90. 被引量：1
8Levit K, Smith C. Health spending rebound continues in 2002[J]. Health Affairs, 2004, 23(1): 147-159. 被引量：1
9Mrazek MF. Comparative approaches to pharmaceutical price regulation in the european union[J]. Croatian Medical Journal, 2002, 43(4): 453-61. 被引量：1
10Bloor K, Maynard A, Freemantle N. Lessons form international experience in controlling pharmaceutical expenditure[J]. British Medical Journal, 1996, 312(7 045): 1 525. 被引量：1
